NWI Management LP Invests $1.43 Million in Axon Enterprise, Inc. (NASDAQ:AXON)

NWI Management LP purchased a new stake in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 2,400 shares of the biotechnology company's stock, valued at approximately $1,426,000.

A number of other institutional investors have also modified their holdings of AXON. Capital World Investors boosted its stake in Axon Enterprise by 86.4% in the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock worth $1,079,145,000 after purchasing an additional 841,772 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Axon Enterprise by 273.8% in the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock worth $659,128,000 after purchasing an additional 812,337 shares in the last quarter. Norges Bank acquired a new stake in Axon Enterprise in the 4th quarter worth approximately $482,081,000. GQG Partners LLC acquired a new stake in Axon Enterprise in the 4th quarter worth approximately $478,349,000. Finally, Vanguard Group Inc. boosted its stake in Axon Enterprise by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company's stock worth $5,019,886,000 after purchasing an additional 275,959 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of recent analyst reports. Needham & Company LLC lifted their target price on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Craig Hallum cut shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. The Goldman Sachs Group lifted their price objective on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday. Barclays lifted their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. Finally, JMP Securities restated an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $652.73.

Axon Enterprise Stock Performance

Shares of NASDAQ:AXON traded up $4.79 during trading on Friday, hitting $733.18. 419,101 shares of the stock traded hands, compared to its average volume of 759,084. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The company has a market cap of $57.08 billion, a price-to-earnings ratio of 189.45, a P/E/G ratio of 5.17 and a beta of 1.24. The company has a fifty day moving average price of $584.61 and a two-hundred day moving average price of $594.51. Axon Enterprise, Inc. has a 52-week low of $273.52 and a 52-week high of $735.68.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.07. The firm had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The business's quarterly revenue was up 31.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.15 EPS. As a group, equities analysts predict that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Insider Buying and Selling

In related news, CEO Patrick W. Smith sold 10,000 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $540.99, for a total value of $5,409,900.00. Following the completion of the sale, the chief executive officer now owns 3,063,982 shares of the company's stock, valued at approximately $1,657,583,622.18. The trade was a 0.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Brittany Bagley sold 3,400 shares of the business's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $700.00, for a total transaction of $2,380,000.00. Following the completion of the sale, the chief financial officer now directly owns 131,833 shares of the company's stock, valued at approximately $92,283,100. The trade was a 2.51% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,764 shares of company stock valued at $14,856,635. 4.40% of the stock is owned by corporate insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.